Intricon to Present at the Virtual 2021 Stifel Healthcare Conference
Intricon Corporation (NASDAQ: IIN) announced that its President and CEO, Scott Longval, will present at the Virtual 2021 Stifel Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intricon Corporation (NASDAQ: IIN) announced that its President and CEO, Scott Longval, will present at the Virtual 2021 Stifel Healthcare Conference. The presentation is scheduled for November 15, 2021, at 10:40 a.m. Eastern Time. Interested parties can access a live and archived webcast of the presentation through the 'Investors' section on the company's website. Intricon specializes in designing and manufacturing medical devices and focuses on advancing clinical outcomes through innovative technology.
Details
News Market Reaction – IIN
The recorded move for IIN in the trading session of this news was +3.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ARDEN HILLS, Minn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that Scott Longval, Intricon’s President and Chief Executive Officer, will present at the upcoming Virtual 2021 Stifel Healthcare Conference.
Intricon is scheduled to present on Monday, November 15, 2021 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.intricon.com.
About Intricon Corporation
Intricon is a joint development manufacturer that integrates micromedical components and assemblies to advance technology across a range of device platforms for global customers. Intricon approaches each engagement with an all-in commitment, working with customers every step of the way- from the earliest idea stages to ongoing production - in order to advance program performance and deliver results. With a focus on key device platforms, Intricon helps advance clinical outcomes by always looking ahead with proactive support and resources through integration of its core competencies. Intricon has facilities in the United States, Asia and Europe. The company's common stock trades under the symbol "IIN" on the NASDAQ Global Market.
Investor Contact
Leigh Salvo
(415) 937-5404
investorrelations@intricon.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.